FUAN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.23 CNY | -0.94% |
|
-3.42% | -3.42% |
| 04-25 | Fuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2023 | CI |
| 04-24 | Fuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,819 | 6,591 | 5,865 | 6,091 | 4,283 | 5,211 |
| Enterprise Value (EV) 1 | 3,079 | 5,845 | 5,558 | 5,995 | 4,293 | 5,107 |
| P/E ratio | -10.7 x | 22.2 x | 27.4 x | -20.5 x | 21.2 x | 23.1 x |
| Yield | - | 0.9% | 1.01% | - | 1.39% | 1.14% |
| Capitalization / Revenue | 1.43 x | 2.37 x | 2.48 x | 2.48 x | 1.77 x | 1.97 x |
| EV / Revenue | 1.15 x | 2.1 x | 2.35 x | 2.44 x | 1.77 x | 1.93 x |
| EV / EBITDA | 8.02 x | 15.4 x | 16.8 x | 18.6 x | 15.5 x | 13 x |
| EV / FCF | 82.7 x | -75.9 x | 119 x | -58.5 x | -66.5 x | 52 x |
| FCF Yield | 1.21% | -1.32% | 0.84% | -1.71% | -1.5% | 1.92% |
| Price to Book | 1.03 x | 1.65 x | 1.43 x | 1.63 x | 1.09 x | 1.26 x |
| Nbr of stocks (in thousands) | 1,189,712 | 1,189,712 | 1,189,712 | 1,189,712 | 1,189,712 | 1,189,712 |
| Reference price 2 | 3.210 | 5.540 | 4.930 | 5.120 | 3.600 | 4.380 |
| Announcement Date | 28/03/19 | 27/03/20 | 30/03/21 | 25/04/22 | 30/03/23 | 24/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2,669 | 2,781 | 2,368 | 2,453 | 2,422 | 2,648 |
| EBITDA 1 | 383.7 | 379.7 | 331.7 | 321.7 | 277.8 | 392.6 |
| EBIT 1 | 242.9 | 235.9 | 176.1 | 147.6 | 94.18 | 184.5 |
| Operating Margin | 9.1% | 8.48% | 7.44% | 6.02% | 3.89% | 6.97% |
| Earnings before Tax (EBT) 1 | -322.7 | 326.8 | 241.1 | -592 | 189.4 | 290.4 |
| Net income 1 | -360 | 292.8 | 209.4 | -296.9 | 204.6 | 231.9 |
| Net margin | -13.49% | 10.53% | 8.84% | -12.1% | 8.45% | 8.76% |
| EPS 2 | -0.3000 | 0.2500 | 0.1800 | -0.2500 | 0.1700 | 0.1900 |
| Free Cash Flow 1 | 37.21 | -77.06 | 46.66 | -102.5 | -64.53 | 98.2 |
| FCF margin | 1.39% | -2.77% | 1.97% | -4.18% | -2.66% | 3.71% |
| FCF Conversion (EBITDA) | 9.7% | - | 14.06% | - | - | 25.02% |
| FCF Conversion (Net income) | - | - | 22.28% | - | - | 42.35% |
| Dividend per Share | - | 0.0500 | 0.0500 | - | 0.0500 | 0.0500 |
| Announcement Date | 28/03/19 | 27/03/20 | 30/03/21 | 25/04/22 | 30/03/23 | 24/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 10.5 | - |
| Net Cash position 1 | 740 | 746 | 307 | 96 | - | 104 |
| Leverage (Debt/EBITDA) | - | - | - | - | 0.0376 x | - |
| Free Cash Flow 1 | 37.2 | -77.1 | 46.7 | -102 | -64.5 | 98.2 |
| ROE (net income / shareholders' equity) | -9.15% | 7.63% | 4.82% | -14.5% | 5.14% | 5.79% |
| ROA (Net income/ Total Assets) | 3.38% | 3.27% | 2.06% | 1.58% | 1.02% | 1.95% |
| Assets 1 | -10,651 | 8,968 | 10,184 | -18,797 | 20,135 | 11,918 |
| Book Value Per Share 2 | 3.100 | 3.350 | 3.450 | 3.140 | 3.320 | 3.480 |
| Cash Flow per Share 2 | 0.5000 | 0.5600 | 0.7200 | 0.8200 | 0.5800 | 0.8300 |
| Capex 1 | 132 | 224 | 345 | 413 | 383 | 216 |
| Capex / Sales | 4.95% | 8.05% | 14.55% | 16.84% | 15.82% | 8.15% |
| Announcement Date | 28/03/19 | 27/03/20 | 30/03/21 | 25/04/22 | 30/03/23 | 24/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -3.42% | 704M | |
| +21.59% | 44.15B | |
| +23.03% | 23.02B | |
| +18.22% | 15.33B | |
| +12.26% | 13.74B | |
| +52.55% | 12.16B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.66B |
- Stock Market
- Equities
- 300194 Stock
- Financials Fuan Pharmaceutical (Group) Co., Ltd.
